Several GLP‐1 receptor agonists are available in Australia for the treatment of type 2 diabetes, of which two, liraglutide and semaglutide, are also indicated for obesity treatment at higher doses (liraglutide 3.0 mg daily and semaglutide 2.4 mg weekly for obesity, and up to 1.8 mg daily and 1.0 mg weekly, respectively, for type 2 diabetes). The gene discussed is GLP1R; the disease is Obesity.